MISSISSAUGA, ON, October 15, 2020 – MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX), a Company focused on becoming the global leader in teledermatology, announces that it has appointed Anthony Milonas and Wayne Cockburn as Directors of the Company, effective immediately. Mr. Milonas and Mr. Cockburn have extensive senior management experience working with medical device and health care growth-stage companies, both nationally and internationally.
Mr. Milonas is President and CEO of Canadian Orthodontic Partners, a company overseeing a national network of orthodontic practices. Mr. Milonas was responsible for the expansion of the group’s number of practices from 28 to approximately 55 and has held senior roles in both large publicly-traded companies as well as privately-held small and mid-sized companies. Mr. Milonas stated, “I am looking forward to working with such a talented team. MedX’s SIAscopy™ combined with its DermSecure™ platform are, in my view, an ideal combination for today’s challenging environment and the shift towards digital health care.”
Mr. Cockburn is President of The Clinic Network Canada, one of Canada’s largest providers of out-of-hospital pain management services. Mr. Cockburn previously founded the medical device company, iTech Medical, leading it through product approval in Europe and Canada. "I am very pleased to be joining the MedX team at such a pivotal time,” Mr. Cockburn said. “ The meticulous development, regulatory and commercialization work that they've done over the past several years has, I believe, put them in a good position to not only become a leader in their field, but also allow them to save the lives of so many people who become affected by skin cancer."
“We are delighted to add two executives of such notable experience to our Board,” noted Rob von der Porten, Chairman of MedX. “Anthony and Wayne have each held multiple leadership roles and have been integral in transforming smaller companies into strong organizations through the optimization of business strategies and operations, the pursuit of strategic partnerships and the building of brand channels. They both have a proven track record of bringing an operational focus in managing and growing healthcare companies and driving the profitable growth and expansion of business at national and international levels. Their insight will be invaluable as we build out the sales pipeline for our SIAscopy™ on Dermsecure™ telemedicine platform.”
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy™ on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy™ is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain.
For Further Information Contact:
Rob von der Porten
MedX Health Corp.
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.